Eli Lilly reported impressive data at the recent American Diabetes Association ('ADA') conference. Its robust pipeline will ...

Amycretin, a new weight-loss treatment from Novo Nordisk, combines two hunger hormones, helping participants lose nearly ...

A new drug called amycretin has shown it can help reduce body weight in two early-phase clinical trials. The drug, which targets both GLP-1 and amylin receptors to help control blood sugar and ...

Novo Nordisk on Friday said full results from early-stage trials show that its experimental drug, amycretin, helped overweight and obese adults lose up to 24% of their weight as the Danish company ...

Once-weekly amycretin, a novel peptide activating GLP-1, amylin, and calcitonin receptors, produced rapid, substantial, and sustained weight loss in adults with overweight or obesity during a ...

Amycretin is a unimolecular long-acting GLP-1 and amylin receptor agonist under development by Novo Nordisk, to provide a treatment for adults with overweight or obesity and as a treatment for ...

Novo Nordisk is in the lead, but not alone. Obesity doctors say they are gearing up for demand, predicted to be high. Some ...

Bagsværd, Denmark, 12 June 2025 – Novo Nordisk today announced that it will advance subcutaneous and oral amycretin into phase 3 development in weight management based on completed clinical ...

Subcutaneous amycretin phase 1 b/2a data on the safety, tolerability and weight loss potential in people with overweight or obesity was published in The Lancet and presented at the American ...

Today, results from two early-phase clinical trials evaluating Novo Nordisk's amycretin, an innovative investigational obesity treatment designed to target appetite regulation, were published in ...